Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (24)

I-03Yumi Yamamoto

Toward a generic PBPK model to predict drug distribution in human brain

Wednesday 10:20-11:50

I-25Abhishek Gulati

Modeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis

Wednesday 10:20-11:50

I-35Xiao Hu

Exposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis

Wednesday 10:20-11:50

I-36Kimberley Jackson

Population Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats.

Wednesday 10:20-11:50

I-43Marija Jovanovic

Effect of Valproic Acid Daily Dose on Phenobarbital Clearance – Nonlinear Mixed Effects Modelling Approach

Wednesday 10:20-11:50

I-44Rasmus Juul Kildemoes

How Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain management

Wednesday 10:20-11:50

I-47Mats Karlsson

Item response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia

Wednesday 10:20-11:50

I-58Mads Kreilgaard

Study design optimization of a morphine analgesia trial using PKPD modelling and simulation

Wednesday 10:20-11:50

II-02

Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients.

Wednesday 15:10-16:30

III-01João Abrantes

A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during Video-EEG monitoring

Thursday 10:05-11:30

III-02Oliver Ackaert

Quantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model

Thursday 10:05-11:30

III-04

Differences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly?

Thursday 10:05-11:30

III-19Irina Bondareva

Population modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data

Thursday 10:05-11:30

III-40Jae Yong Chung

Ethnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer’s Disease

Thursday 10:05-11:30

IV-09Shinji Shimizu

PBPK modeling of CNS distribution for risperidone and its active metabolite, paliperidone

Thursday 15:15-16:40

IV-24Amit Taneja

Development of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats

Thursday 15:15-16:40

IV-25Paulo Teixeira

Population Pharmacokinetic Model of Valproic Acid in Adult Patients: an Update

Thursday 15:15-16:40

IV-30Iñaki F. Trocóniz

Population pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects

Thursday 15:15-16:40

IV-35Sven van Dijkman

A PKPD Hidden Markov Model for Lamotrigine in all age groups

Thursday 15:15-16:40

IV-37Eline van Maanen

Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys.

Thursday 15:15-16:40

IV-40Marc Vandemeulebroecke

Identifying neuropsychological domains with high information on early signs of cognitive decline: An application of Item Response Theory in the Basel Study on the Elderly

Thursday 15:15-16:40

IV-41

Analysis of Sleep Changes Induced by Citalopram: A Population Approach

Thursday 15:15-16:40

IV-44Shaonan Wang

Exposure-response analysis of Axomadol in patients suffering from hip and/or knee-joint osteoarthritis pain

Thursday 15:15-16:40

IV-57Li Zhu

Population Pharmacokinetic/Pharmacodynamic Models for the Heart Rate Effects of BMS-820836, a Triple Monoamine Reuptake Inhibitor, in a Thorough QT Study

Thursday 15:15-16:40